Close Menu

Castle Biosciences

BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.

Palmetto GBA issued final local coverage determination for the tissue-based, 31-gene expression test, which determines a patient’s risk for metastatic disease.  

The approvals allow the company to offer its PCR-based expression profile cancer risk tests in the state.

The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.

Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.

The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.

The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.

The first tranche of the targeted $20 million financing round will be used to accelerate adoption of the company's melanoma test.

Pages

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.